A new study in mice suggests that blockade of β-catenin signalling has promise as a new therapeutic strategy against MEN1-deficient pancreatic neuroendocrine tumours (NETs). Lack of menin, the protein encoded by MEN1, activates β-catenin signalling in mouse and human pancreatic NETs. Genetic or pharmacological suppression of β-catenin signalling inhibited tumour growth, decreased hyperinsulinaemia and hypoglycaemia, and improved survival in mice with MEN1-deficient pancreatic NETs.
References
Jiang, X. et al. Targeting β-catenin signaling for therapeutic intervention in MEN1-deficient pancreatic neuroendocrine tumours. Nat. Commun. 5, 5809 (2014)
Rights and permissions
About this article
Cite this article
Blocking β-catenin signalling—a future therapy for pancreatic neuroendocrine tumours?. Nat Rev Endocrinol 11, 132 (2015). https://doi.org/10.1038/nrendo.2014.241
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2014.241
